tiprankstipranks

David Scadden Insider Profile

4 Followers
David Scadden, Director at Agios Pharma, holds 15.48K shares in Agios Pharma (Ticker: AGIO), holds 808.67K shares in Dianthus Therapeutics (Ticker: DNTH), holds ― shares in Editas Medicine (Ticker: EDIT).
tipranks
David Scadden

David Scadden
Agios Pharma (AGIO)
Director

Ranked #57,776 out of 100,516 Corporate Insiders

Profitable Transactions

50%
1 out of 2 Profitable Transactions

Average Return

-8.60%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$20M
97.23%
2.77%
0.00%
0.00%
A breakdown of David Scadden's holdings

Insider Roles

Dianthus Therapeutics
(DNTH)
Director
Agios Pharma
(AGIO)
Director
Editas Medicine
(EDIT)
Director
Carisma Therapeutics
(CARM)
Director
Roles that David Scadden holds in companies

Most Profitable Insider Trade

Stock:
Dianthus Therapeutics
(DNTH)
Rating:Informative Buy
Date:Jun 27, 2018 - Jun 27, 2019
Return:+4.90%
The most profitable trade made by David Scadden

David Scadden's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Agios Pharma
Dec 13, 2024
Director
Uninformative Buy
3.62K
$545.31K
Dianthus Therapeutics
Jun 27, 2018
Director
Uninformative Buy
$19.14M
Editas Medicine
Director
Carisma Therapeutics
Director
List of latest transactions for each holding click on a transaction to see David Scadden's performance on stock

David Scadden insider profile FAQ

What is the percentage of profitable transactions made by David Scadden?
The percentage of profitable transactions made by David Scadden is 50%.
    What is the average return per transaction made by David Scadden?
    The average return per transaction made by David Scadden is -8.60%.
      What stocks does David Scadden hold?
      David Scadden holds: AGIO, DNTH, EDIT, CARM stocks.
        What was David Scadden’s latest transaction?
        David Scadden latest transaction was an Uninformative Buy of $3.62K.
          What was David Scadden's most profitable transaction?
          David Scadden’s most profitable transaction was an Informative Buy of DNTH stock on June 27, 2018. The return on the trade was 4.90%.
            What is David Scadden's role in Agios Pharma?
            David Scadden's role in Agios Pharma is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.